Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurrayScott D SolomonSilvio E InzucchiLars KøberMikhail N KosiborodFelipe A MartinezPiotr PonikowskiMarc S SabatineInder S AnandJan BělohlávekMichael BöhmChern-En ChiangVijay K ChopraRudolf A de BoerAkshay S DesaiMirta DiezJaroslaw DrozdzAndrej DukátJunbo GeJonathan G HowlettTzvetana KatovaMasafumi KitakazeCharlotta E A LjungmanBéla MerkelyJose C NicolauEileen O'MearaMark C PetriePham N VinhMorten SchouSergey TereshchenkoSubodh VermaClaes HeldDavid L DeMetsKieran F DochertyPardeep S JhundOlof BengtssonMikaela SjöstrandAnna-Maria Langkildenull nullPublished in: The New England journal of medicine (2019)
Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).